REG - Arecor Therapeutics - Notice of Results

Arecor TherapeuticsAnnouncement

19/09/2024 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240919:nRSS9311Ea&default-theme=true

RNS Number : 9311E  Arecor Therapeutics PLC  19 September 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

NOTICE OF INTERIM RESULTS

 

Cambridge, UK, 19 September 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
will announce its Interim Results for the six months ended 30 June 2024 on
Thursday 26 September 2024.

 

Sarah Howell, Chief Executive Officer, will host an in-person briefing for
analysts at 9:30am BST on the day of the results at the offices of ICR
Consilium, 85 Gresham Street, London, EC2V 7NQ. There will also be a live
webcast and conference call with a Q&A session.

 

For more details or to attend the briefing, please contact
arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

-ENDS-

 

 For more information, please contact:

 Arecor Therapeutics plc                                                               www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer                                              Tel: +44 (0) 1223 426060

                                                                                       Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                                      Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint                                                                Tel: +44 (0) 203 705 9321
 Broker)

 Nigel Barnes, Satheesh Nadarajah

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville                                           Tel: +44 (0) 20 3709 5700

                                                                                       Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

 

Notes to Editors

 

About Arecor

 

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBSGDCLBBDGSC